-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Moving forward and enlightening the future together! From January 6 to 8, 2023, the 3rd China Hematology Development Conference was grandly opened
.
THE CONFERENCE WAS HOSTED BY THE CHINESE ACADEMY OF MEDICAL SCIENCES AND PEKING UNION MEDICAL COLLEGE, THE HOSPITAL OF HEMATOLOGY, CHINESE ACADEMY OF MEDICAL SCIENCES (INSTITUTE OF HEMATOLOGY, CHINESE ACADEMY OF MEDICAL SCIENCES), TIANJIN MEDICAL HEALTH RESEARCH INSTITUTE, CHINESE ACADEMY OF MEDICAL SCIENCES, STATE KEY LABORATORY OF EXPERIMENTAL HEMATOLOGY, NATIONAL CLINICAL RESEARCH CENTER FOR HEMATOLOGICAL DISEASES, CHINESE JOURNAL OF HEMATOLOGY, CELL ECOLOGY HAIHE LABORATORY, CHINESE PHYSIOLOGICAL SOCIETY HEMATOLOGY PROFESSIONAL COMMITTEE, TIANJIN SOCIETY OF HEMATOLOGY AND REGENERATIVE MEDICINE, BLOOD SCIENCE, With the theme of "Big Blood, Big Health, Big Health - Drawing a New Blueprint for the Development of Hematology", Gobo Medical Group joined hands with more than 100 experts and scholars at home and abroad to discuss cutting-edge achievements in the field of hematology and seek the construction and vigorous development
of hematology.
On this occasion, Yimaitong sincerely invites Professor Hu Yu, President of Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, to be interviewed to share his insights
on coagulation diseases and the development of hematology in China.
Professor Hu Yu
Member of the 13th National Committee of the Chinese People's Political Consultative Conference
President of Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Director of the Institute of Hematology, Huazhong University of Science and Technology
Chairman-elect of Hematology Branch of Chinese Medical Association (leader of thrombosis and hemostasis group)
Member of the Standing Committee of the Internal Medicine Branch of the Chinese Medical Association
Vice President of Hematologist Branch of Chinese Medical Doctor Association
Vice Chairman of the Experimental Hematology Society of the Chinese Pathophysiology Society
Member of the Education Committee of the International Society of Thrombosis and Haemostasis
Chairman of Hematology Branch of Hubei Medical Association
Editor-in-Chief of Journal of Clinical Internal Medicine/Journal of Clinical Emergencies
Associate Editor of Chinese Journal of Hematology/Journal of Clinical Hematology
Associate Editor of Chinese Hospital Management / Editorial Board Member of Chinese Journal of Hospital Management
Associate Editor of Thrombosis Research/Thrombosis and Haemostasis
Yimaitong: Thrombosis and hemostasis is a multi-professional clinical interdisciplinary discipline, thrombosis and bleeding diseases seriously threaten the survival and quality of life of patients, can you please introduce the development status and trend in the field of thrombosis and hemostasis?
Professor Hu Yu
Thrombosis and hemostasis involve many clinical specialties, and the improvement of the diagnosis and treatment of thrombosis and bleeding diseases depends on close multidisciplinary cooperation
.
In recent years, the field of thrombosis and hemostasis has developed rapidly, thrombosis diagnosis and treatment technology and related instruments and equipment are constantly updated, the diagnosis and treatment of coagulation diseases has been basically intelligentized, such as molecular diagnosis for thrombophilia, gene chip/biochip, etc.
The promotion and application of gene chips/biochips has become clinically feasible at the molecular level, and it has obvious advantages in the early diagnosis of diseases, and the future prospects are considerable.
In addition to the increasing level of diagnosis, in the field of thrombosis and hemostasis, new anticoagulant drugs are also emerging, which can accurately act on the target at the cellular molecular level, with high specificity and less side effects, such as rivaroxaban and other drugs in clinical application almost no need for laboratory monitoring, so it strengthens the application of a new generation of anticoagulant drugs or some targeted therapy drugs in coagulation diseases, which is also of great significance to the improvement of diagnosis and treatment level
。
In addition, gene therapy has also made breakthroughs in recent years, whether it is hemophilia or other coagulation diseases, such as venous thrombosis, solving genetic defects from the molecular level will become one of the future research hotspots and will also be an important development trend
in the future.
Medical Pulse Communication: The mechanism of coagulation problems related to coagulation diseases or other triggers is complex, diagnosis and treatment are difficult, and patients often have poor prognosis, how do you think the diagnosis and treatment of coagulation diseases in China should be improved?
Professor Hu Yu
The etiology of coagulation diseases is complex, diagnosis and treatment are difficult, and some coagulation diseases are also related to genetic factors, which also make their treatment difficult
.
In order to further improve the diagnosis and treatment of coagulation diseases in China, first, it is necessary to strengthen the application of laboratory monitoring in the diagnosis and treatment of
coagulation diseases.
Because for coagulation disorders, whether it is hemostasis or anticoagulation, it is necessary to strike a balance between bleeding and coagulation, and too strong force on either side will make coagulation and anticoagulation imbalance
.
If the ability to stop bleeding is too strong, blood clots may form; If the anticoagulation is too strong, bleeding can occur due to inadequate hemostasis
.
Various tests can be used to monitor the level of hemostasis and anticoagulation therapy, such as the detection of coagulation items, the application of thromboelastograms, and the application of INR values
.
Second, because the diagnosis and treatment of coagulation diseases involves multiple clinical specialties, it is necessary to implement multidisciplinary cooperation for basic research and clinical diagnosis and treatment
.
For patients with thrombosis, the treatment options include: conservative anticoagulation therapy in internal medicine, thrombolysis or thrombectomy in interventional medicine, and surgical treatment in surgery
.
From the patient's point of view, how to get the best treatment plan requires multidisciplinary joint discussion and cooperation, comprehensive assessment according to the patient's physical condition, and individualized treatment
.
Third, strengthen the integration of basic research and clinical application, so as to promote the transformation of more basic research results into clinically usable diagnosis and treatment methods or technologies, and help improve
the level of diagnosis and treatment.
For example, many commonly used anticoagulants are initially based on factor X, and then after clinical research, they are finally transformed into clinical applications
.
Yimaitong: Chimeric antigen receptor T (CAR-T) cells are currently a popular therapy in the field of hematological tumors, and coagulation abnormalities are one of its important complications, how do you think it should be treated and managed?
Professor Hu Yu
CAR-T is currently one of the popular immunotherapies for hematological tumors and some solid tumors, bringing long-term survival hope to countless patients with relapsed/refractory hematologic malignancies and other tumors
.
However, as an emerging treatment method, we should pay attention to its safety while paying attention to its advantages, that is, paying attention to the control of adverse reactions
related to CAR-T treatment.
In addition to cytokine release syndrome (CRS) and neurotoxicity, coagulopathy associated with CAR-T therapy cannot be ignored
.
During the application of CAR-T, cytokine release stimulates the vascular endothelium and coagulation factors, resulting in coagulation imbalance, resulting in some coagulation-related changes characterized by bleeding and/or thrombosis, accompanied by decreased platelet levels and coagulation dysfunction
.
Based on this, we have published the "Chinese Expert Consensus on the Management of Coagulation Dysfunction Related to CAR-T Cell Therapy" in the Chinese Journal of Hematology (English Edition), emphasizing that its treatment principles are early diagnosis, accurate assessment, elimination of triggers, and graded intervention
.
Coagulation dysfunction related to CAR-T therapy is mainly induced by CRS, so how to control the occurrence and severity of CRS and remove high-risk factors for the occurrence of coagulation dysfunction is particularly important.
In addition, timely use of cytokine inhibitors or glucocorticoids to control the severity of CRS is critical
.
At the same time, in clinical applications, once bleeding or thrombosis occurs, the extent, degree and possible risk to patients should be timely, accurate and comprehensively assessed; The Chinese Disseminated Intravascular Coagulation Diagnosis Score System (CDSS) and the DIC Scoring System of the International Society of Thrombosis and Haemostasis can also be used to carry out early diagnosis and timely treatment of bleeding and thrombosis problems.
In the clinic, anticoagulant therapy and antifibrinolytic therapy can also be applied according to the specific situation to ensure patient safety
.
Yimaitong: With the gradual liberalization of epidemic prevention and control in China, what is the difference in the management mode of hematological cancer patients compared with before? What new challenges will hematologists face? How do you suggest responding?
Professor Hu Yu
In response to the current changes in China's anti-epidemic policy, the "Class B tube" will be implemented for new coronavirus infection, which significantly increases the risk of new coronavirus infection for a certain period of time
.
However, patients with hematological tumors have low immune function, and after anti-tumor treatment such as chemotherapy, radiotherapy, and transplantation, their immunity is further reduced in a short period of time, and they are more likely to be complicated by new coronavirus infection; And because the resistance is weaker, the infection is also more likely to progress, from mild to severe to critical, eventually leading to higher mortality
.
Therefore, patients with blood diseases are quite different from patients with other specialties, and it is necessary to focus on and accurately evaluate the impact of
the epidemic liberalization on patients with blood diseases.
For some patients with hematological tumors who are clinically critical and have underlying diseases, the demand for blood after infection with the new coronavirus increases, and more attention needs to be paid to ensuring the timely supply
of blood products after the epidemic is released.
In addition, since some patients with blood diseases need to be treated with transplantation or CAR-T, the choice of treatment method and treatment intensity needs to fully assess the patient's possible infection risk and severity, and the application of transplantation or CAR-T and other technologies to patients with new coronavirus-positive infection needs to be closely monitored or postponed
.
All in all, with the liberalization of domestic epidemic prevention and control, the risk of new coronavirus infection will increase for a certain period of time, and the immune function of patients with blood diseases is low, and hematologists should conduct a comprehensive assessment when choosing treatment methods and treatment timings to provide a strong guarantee
for patient safety.
Yimaitong: China Hematology Development Conference has been successfully held for three sessions, constantly presenting a high-quality academic feast for experts and scholars in the field of hematology, the theme of this year's conference is "big blood, big health", can you please look forward to the key direction of the future development of hematology in China?
Professor Hu Yu
The China Hematology Development Conference has lasted for three times, each of which has achieved "high point standing and precise positioning", accurately grasped the key directions and trends of hematology development, and implemented the concept
of "great hygiene and great health" based on the national strategic needs.
In the future, the key direction of the development of hematology in China, I personally believe that there are the following aspects:
First, the application of new technologies, such as the continuous optimization of classic transplantation technology and the rapid development of CAR-T technology
in recent years.
Driven by the power of science and technology, more new products, new treatment methods and new technologies
will continue to emerge in the future.
Second, new therapies continue to emerge.
With the advancement of science and technology and the development of new drugs, the history of some diseases without treatment has become a thing of the past, such as gene therapy to bring cure possibilities to hemophilia patients, innovative drugs to benefit more patients with paroxysmal nocturnal hemoglobinuria, targeted drugs to significantly improve the treatment benefits of myeloid leukemia patients, etc.
, new drug research and development results will drive continuous progress
in all aspects of hematology.
Third, driven by the national strategy and promoted by the China Hematology Development Conference, more new guidelines/consensuses and new grassroots norms with Chinese characteristics will be formed, so that the tentacles of hematology development will extend and penetrate from central cities to grassroots and even rural areas, thereby improving China's overall health level and helping the construction of
a healthy China 。 Moreover, multiple myeloma, chronic myeloid leukemia and other blood diseases are gradually developing into chronic diseases, and their treatment mode may shift to community management or grassroots hospital management in the future, which especially needs to further improve the standardized diagnosis and treatment capacity of China's grassroots level and help promote the improvement
of China's overall health level.
: Arya Reviewed: Moon Typesetting: Moly Executive: Moly
Disclaimer: This platform is designed to deliver more medical information
to healthcare professionals.
The content published on this platform cannot replace professional medical guidance in any way, nor should it be regarded as diagnosis and treatment advice
.
If such information is used for purposes other than understanding medical information, this platform does not assume relevant responsibilities
.
The content published by this platform does not mean that it agrees with its description and views
.
If copyright issues are involved, please contact us and we will deal with
it as soon as possible.
Poke "Read Original" to watch the wonderful replay of the meeting
